Novel Drug Helped HIV Patients Achieve Viral Suppression
More than 80% of heavily treatment-experienced HIV patients with multi-drug resistance who received long-acting subcutaneous lenacapavir along with an optimized background regimen experienced viral suppression at week 26, according to results of an ongoing randomized phase II/III trial. Overall, 81% of patients randomized to the investigational agent lenacapavir with an optimized background regimen of antiretroviral […]